Charcot Neuroarthropathy (Charcot Foot)

1. Overview

Charcot neuroarthropathy (CN), commonly referred to as Charcot foot, is a progressive destructive arthropathy affecting the bones and joints of the foot and ankle in patients with peripheral neuropathy. The condition is most frequently encountered in individuals with long-standing diabetic peripheral neuropathy, though any cause of sensory loss can predispose to this devastating complication. [1,2]

The hallmark of acute Charcot foot is a hot, red, swollen foot that is characteristically painless or minimally painful due to the underlying neuropathy. This presentation mimics infection (cellulitis or osteomyelitis), making clinical differentiation challenging yet critical. The pathological process involves repetitive unrecognized microtrauma to an insensate foot, leading to progressive bone fragmentation, joint dislocation, and architectural collapse. Without prompt recognition and aggressive offloading, the midfoot collapses into the classic "rocker-bottom" deformity, creating abnormal plantar pressure points that lead to ulceration, infection, and ultimately lower limb amputation. [3,4]

The condition affects approximately 0.1-0.5% of all diabetic patients, with significantly higher prevalence (up to 13%) in those with established peripheral neuropathy. [5] Early diagnosis and immediate immobilization are crucial—the cornerstone of acute management is complete offloading with a Total Contact Cast (TCC) until the acute inflammatory phase resolves, a process that typically requires 3-6 months. [6] Long-term protective footwear and vigilant foot care are essential to prevent recurrence and complications. The prognostic impact is substantial: patients with Charcot foot have a 5-year mortality rate approaching 30%, often exceeding that of many malignancies. [7]

---

2. Epidemiology

Incidence and Prevalence

The true incidence of Charcot neuroarthropathy is difficult to establish due to underdiagnosis and misdiagnosis, particularly in early stages. Population-based studies estimate:

Peak Incidence

• Age: Most commonly diagnosed in the 5th-6th decade (mean age 57 years) [10]
• Duration of diabetes: Typically occurs after 10-15 years of diabetes duration [8]
• HbA1c: Poor glycaemic control is associated with higher risk, though Charcot can occur with well-controlled diabetes [11]

Risk Factors

The development of Charcot neuroarthropathy requires the presence of peripheral neuropathy, but additional risk factors modulate individual susceptibility:

Causes of Neuropathic Arthropathy Beyond Diabetes

While diabetes accounts for > 95% of modern Charcot foot cases, historical and rare causes include:

---

3. Aetiology and Pathophysiology

Dual Pathogenic Theories

The pathogenesis of Charcot neuroarthropathy involves complex interplay between biomechanical (neurotraumatic) and neurovascular mechanisms, both driven by the underlying peripheral neuropathy. Current understanding recognizes both theories as complementary rather than competing. [16,17]

Neurotraumatic Theory

Loss of protective sensation allows:

1. Unperceived repetitive microtrauma during weight-bearing activities
2. Continued ambulation on microfractured bones due to absence of pain
3. Progressive bone and joint destruction without behavioral modification
4. Proprioceptive deficit leading to abnormal foot positioning and gait

Neurovascular Theory

Autonomic neuropathy causes:

1. Arteriovenous shunting → increased bone blood flow → bone hypervascularization
2. Enhanced osteoclastic bone resorption mediated by RANKL-RANK-OPG pathway dysregulation [18]
3. Periarticular osteopenia → increased susceptibility to fracture
4. "Hot foot" clinically apparent due to arteriovenous shunting

Molecular Pathophysiology

Recent research has elucidated key molecular mechanisms:

RANKL-RANK-OPG Axis Dysregulation [18]:

• Receptor Activator of Nuclear Factor-κB Ligand (RANKL) is markedly elevated in active Charcot foot
• RANKL binds RANK receptors on osteoclasts → enhanced bone resorption
• Osteoprotegerin (OPG), a natural RANKL inhibitor, is relatively deficient
• This creates a pro-osteoclastic environment, accelerating bone destruction

Inflammatory Cytokines [19]:

• TNF-α and IL-1β levels elevated in acute Charcot
• IL-6 drives inflammatory response
• Pro-inflammatory milieu promotes both bone resorption and soft tissue inflammation

Autonomic Dysfunction:

• Loss of sympathetic tone → vasodilation → increased bone perfusion
• Temperature differential between affected and contralateral foot typically > 2°C [6]

Anatomical Patterns of Involvement

The Sanders-Frykberg classification describes five anatomical patterns based on location of primary involvement:

Multiple patterns may coexist in the same foot; 20% of patients have involvement of more than one anatomical region. [20]

---

4. Clinical Presentation

Acute Charcot Foot (Eichenholtz Stage 0-I)

The acute presentation is pathognomonic but frequently misdiagnosed:

Cardinal Features

Key Differentiating Feature: The Elevation Test

A critical clinical maneuver to differentiate Charcot from infection:

Clinical Pearl: This test has approximately 80% sensitivity for differentiating Charcot from infection, though neither diagnosis can be excluded on clinical grounds alone. [22]

Prodromal Phase (Eichenholtz Stage 0)

Some patients report:

• Minor trauma or trivial injury weeks before onset
• Gradual onset of swelling
• Skin temperature changes
• Normal radiographs despite clinical findings
• Bone marrow oedema on MRI

Chronic/Healed Charcot Foot (Eichenholtz Stages II-III)

Once the acute inflammatory phase has resolved (3-18 months), residual deformity becomes the dominant feature:

Natural History: Without protective footwear, 40-60% of chronic Charcot feet develop ulceration within 5 years. [23]

---

5. Clinical Examination

Systematic Foot Examination in Suspected Charcot Foot

Inspection

Both feet should always be examined comparatively

• Skin colour: Erythema, cyanosis, dependent rubor
• Swelling: Diffuse vs. localized; compare ankle girths
• Deformity: Arch collapse, rocker-bottom, bony prominences
• Skin integrity: Ulcers, callus, fissures, previous amputation sites
• Nails: Onychomycosis, ingrown nails, signs of self-care ability

Palpation

Temperature Assessment (CRITICAL):

• Use infrared thermometer or back of hand
• Measure multiple sites on both feet (dorsal, plantar, medial, lateral)
• Temperature differential > 2°C is strongly suggestive of active Charcot [6]
• Document actual temperatures, not just subjective impression

Bony Palpation:

• Tenderness (may be absent despite active process)
• Palpable step-off or architectural abnormality
• Crepitus (suggests fracture or joint destruction)

Pulses:

• Dorsalis pedis and posterior tibial pulses
• Paradoxically bounding in acute Charcot (hyperperfusion)
• Absent pulses suggest concurrent PAD (worsens prognosis)

Neurological Assessment

Mandatory in all cases to document neuropathy severity:

Sensory Testing:

• 10g Semmes-Weinstein monofilament test (key screening tool)
  • Test 9 plantar sites
  • Unable to perceive = loss of protective sensation
• Vibration sense: 128 Hz tuning fork at hallux and medial malleolus
• Joint position sense: Test hallux and ankle
• Pinprick: Light touch vs. sharp (spinothalamic pathway)

Motor Testing:

• Foot dorsiflexion, plantarflexion
• Toe extension, flexion
• Intrinsic muscle wasting (clawing)

Reflexes:

• Ankle reflex (usually absent in significant neuropathy)

Vascular Assessment

Even with bounding pulses, formal vascular assessment is essential:

• Palpable pulses: Grade 0-3+
• Ankle-Brachial Pressure Index (ABPI):
  • "Normal: 0.9-1.2"
  • "Arterial disease: less than 0.9"
  • False elevation > 1.3 in diabetes due to medial arterial calcification
• Toe-Brachial Pressure Index (TBPI): More reliable in diabetes
  • "Normal: > 0.7"
  • "PAD: less than 0.7"
• Capillary refill time: less than 2 seconds normal

Gait Assessment (if safe to mobilize)

• Weight-bearing pattern
• Ankle stability
• Propulsive capacity
• Compensatory mechanisms

---

6. Differential Diagnosis

The acute red, hot, swollen foot in a diabetic patient requires systematic consideration of multiple diagnoses:

CRITICAL POINT: Charcot and infection (cellulitis or osteomyelitis) can coexist. Up to 25% of acute Charcot presentations have concurrent infection, particularly if ulceration is present. [22] Both require aggressive treatment.

---

7. Investigations

Imaging Modalities

Plain Radiographs

First-line investigation — weight-bearing AP, lateral, and oblique views of both feet

Specific Radiographic Signs:

• "Bag of bones" appearance (multiple bone fragments)
• "Pencil-in-cup" deformity (severe joint destruction)
• Midfoot collapse with plantar subluxation
• Loss of Meary's angle (disrupted longitudinal arch alignment)
• Periosteal reaction (may mimic osteomyelitis)

Serial radiographs at 2-4 week intervals during acute phase to monitor progression and guide treatment duration. [6]

Magnetic Resonance Imaging (MRI)

Indications:

• Clinical suspicion with normal plain radiographs (Stage 0)
• Differentiation from osteomyelitis
• Surgical planning

MRI Findings in Acute Charcot:

• Bone marrow oedema (low T1, high T2/STIR signal)
• Periarticular distribution
• Subchondral fractures
• Joint effusions
• Soft tissue oedema

Charcot vs. Osteomyelitis on MRI:

Limitation: MRI often cannot definitively distinguish Charcot from osteomyelitis; clinical correlation is essential. Specificity for osteomyelitis is only 50-60% in Charcot population. [24]

Nuclear Medicine Imaging

White Blood Cell (WBC) Scan with Technetium-99m:

• Increased uptake in infection
• Variable in Charcot (both false positives and negatives)
• Combined WBC/marrow scan improves specificity

18F-FDG PET/CT:

• Emerging modality
• High uptake in both Charcot and infection (limited specificity)
• May help localize infection when combined with clinical features

In practice: Nuclear medicine imaging has not proven superior to MRI and is reserved for equivocal cases. [24]

Computed Tomography (CT)

Indications:

• Surgical planning (detailed bony anatomy)
• Assessment of coalition/consolidation
• 3D reconstruction for complex deformities

Advantages: Superior bony detail compared to MRI Disadvantages: Radiation exposure; poor soft tissue characterization

Laboratory Investigations

CRITICAL: Normal inflammatory markers do not exclude Charcot neuroarthropathy. Up to 40% of acute Charcot cases have normal WCC and CRP. [22]

Probe-to-Bone Test

In the presence of foot ulceration:

• Positive probe-to-bone (metal probe contacts hard tissue through ulcer base) has:
  • Sensitivity 87% for osteomyelitis
  • Specificity 83% [25]
• Strongly suggests concurrent osteomyelitis requiring antibiotics ± surgical debridement

Bone Biopsy

Gold standard for diagnosing osteomyelitis when uncertainty persists despite imaging:

• Histopathology + microbiological culture
• Specificity > 95%
• Reserved for equivocal cases or pre-operative planning

---

8. Eichenholtz Classification: Staging System

The Eichenholtz classification, first described in 1966, remains the standard staging system for Charcot neuroarthropathy, guiding both prognosis and treatment duration. [26]

Clinical Application

Stage 0: Often missed because radiographs are normal. MRI is critical if clinical suspicion high.

Stage I: High-risk period for catastrophic collapse; aggressive offloading essential.

Stage II: Transition phase; premature return to weight-bearing risks re-activation.

Stage III: Structural changes irreversible; focus on complication prevention.

Progression is not inevitable: Early Stage 0 or I recognition with immediate TCC can prevent deformity in 70-80% of cases. [6]

---

9. Management

Principles of Charcot Foot Management

1. Early recognition and diagnosis (often delayed by average of 7-29 weeks) [27]
2. Immediate and complete offloading (cornerstone of treatment)
3. Serial monitoring (clinical, thermometry, radiographic)
4. Multidisciplinary team approach (diabetologist, podiatrist, orthotist, orthopedic surgeon)
5. Long-term protective strategies (footwear, education, surveillance)
6. Prevention of complications (ulceration, infection, amputation)

Acute Phase Management (Eichenholtz Stages 0-I)

Offloading: The Gold Standard

Total Contact Cast (TCC) [6,28]:

Rationale: Provides uniform pressure distribution, complete immobilization, and forces compliance (non-removable).

Evidence: Systematic reviews show TCC is the most effective offloading modality for acute Charcot, with:

• Foot temperature normalization in 80-90% of cases
• Deformity prevention in 70-80%
• Healing time of 3-6 months average

Technique:

• Minimal padding cast applied directly to skin
• Well-molded to foot contours
• Window over ulcer if present
• Changed weekly initially, then every 2 weeks
• Continued until skin temperature difference less than 2°C between feet for 2 consecutive weeks

Contraindications to TCC:

• Active infection (relative contraindication—must be treated concurrently)
• Severe peripheral arterial disease (risk of pressure necrosis)
• Significant oedema (cast becomes loose)
• Patient unable to safely mobilize with cast

Alternative Offloading Devices

Compliance Reality: Studies using activity monitors show patients in RCW are non-compliant 40-60% of the time. TCC or iTCC enforces compliance. [29]

Pharmacological Adjuncts

Bisphosphonates (emerging evidence):

Rationale: Inhibit osteoclast-mediated bone resorption

Evidence:

• Small RCTs show pamidronate (intravenous) or alendronate (oral) may:
  • Reduce bone turnover markers
  • Decrease foot temperature more rapidly
  • Shorten treatment duration by 4-6 weeks [30]
• Not yet standard of care; further trials needed
• NICE does not currently recommend bisphosphonates for Charcot

Dosing (from trial data):

• Pamidronate 60-90 mg IV monthly for 6 months, OR
• Alendronate 70 mg PO weekly

Other Pharmacological Considerations:

• Optimize glycaemic control: HbA1c less than 7% target
• Vitamin D supplementation: Optimize bone health (aim 25-OH vitamin D > 75 nmol/L)
• Calcium supplementation: If dietary intake insufficient
• Antibiotics: If concurrent infection proven or suspected

Transition Phase Management (Eichenholtz Stage II)

When to transition from TCC:

• Skin temperature difference less than 2°C for 2 consecutive measurements 1 week apart
• Clinical resolution of erythema and oedema
• Radiographic evidence of coalescence/early consolidation
• Typical duration: 3-6 months, though can be > 12 months in severe cases

Transition Protocol:

1. Gradual return to weight-bearing in CROW walker or custom AFO (ankle-foot orthosis)
2. Continue temperature monitoring daily at home (infrared thermometer)
3. Rule: If temperature difference increases to > 2°C, return to non-weight-bearing TCC
4. Serial radiographs every 4-6 weeks
5. Custom footwear with rocker-bottom sole and molded insoles

Chronic Phase Management (Eichenholtz Stage III)

Lifelong Protective Strategies:

Footwear (CRITICAL for preventing recurrence and ulceration):

• Custom-molded orthoses with total contact insoles
• Extra-depth therapeutic shoes (Grade 1-3 diabetic footwear)
• Rocker-bottom soles to reduce forefoot pressure
• CROW device for unstable or severe deformity
• Regular review and replacement (every 6-12 months)

Surveillance:

• Podiatry review every 1-3 months
• Daily patient self-examination
• Annual vascular and neurological assessment
• Immediate review if temperature elevation, swelling, or skin breakdown

Patient Education:

• Recognition of warning signs (warmth, swelling, redness)
• Proper footwear compliance
• Glycaemic control
• Smoking cessation
• Foot hygiene and nail care

Surgical Management

Indications for surgery:

1. Unstable deformity refractory to conservative management
2. Recurrent ulceration over bony prominence despite optimal footwear
3. Infected ulcer with underlying osteomyelitis requiring debridement
4. Ankle instability compromising mobility

Timing: Surgery should ideally be performed in Eichenholtz Stage III (consolidated phase) due to:

• Lower infection risk
• Better bone quality for fixation
• Reduced fracture/non-union risk

Surgical Options:

Surgical Challenges:

• Poor bone quality (osteopenic, sclerotic)
• Impaired healing (neuropathy, vasculopathy)
• High infection risk (20-30%) [31]
• Non-union rate 20-40%
• Prolonged immobilization required (6-12 months)

Enhanced Surgical Protocols:

• Superconstructs (stronger fixation crossing multiple joints)
• Bone grafting or bone graft substitutes
• Prolonged non-weight-bearing (3-6 months post-op)
• Bisphosphonate therapy (emerging evidence)

---

10. Complications and Prognosis

Short-Term Complications

Long-Term Complications

Mortality

5-year mortality: 28-30%, comparable to many malignancies [7]

Causes of death:

• Cardiovascular disease (most common)
• Sepsis secondary to infected foot
• Complications of amputation
• Renal failure

Predictors of poor outcome:

• Delayed diagnosis (> 3 months)
• Lack of offloading compliance
• Concurrent peripheral arterial disease (PAD)
• Chronic kidney disease
• Recurrent ulceration
• Low socioeconomic status (affects access to podiatry, footwear)

Prognostic Factors

---

11. Guidelines and Evidence-Based Recommendations

NICE Guideline NG19: Diabetic Foot Problems (2015, updated 2019)

Key Recommendations for Charcot Foot:

1. Suspect acute Charcot in anyone with diabetes and:

   • Acute hot, red, swollen foot
   • Foot deformity
   • Even if no pain (absence of pain due to neuropathy)

2. Urgent referral to multidisciplinary diabetic foot team within 1 working day

3. Offloading: Provide non-removable offloading device (TCC or equivalent) while awaiting specialist assessment

4. Imaging: Arrange X-ray and consider MRI if X-ray normal

5. Treatment: Continue offloading until:

   • Temperature difference less than 2°C
   • Clinical signs resolved
   • Radiographic consolidation

6. Long-term: Lifelong specialist podiatry, custom footwear, annual review

Strength of recommendations: Based on moderate-quality observational evidence (no RCTs exist for ethical reasons—withholding offloading would be harmful)

International Working Group on the Diabetic Foot (IWGDF) Guidance (2023)

Recommendations:

• Immediate non-weight-bearing or TCC for all suspected acute Charcot
• Temperature monitoring as objective endpoint (> 2°C differential = active)
• Minimum 3 months immobilization, often 6-12 months
• Consider bisphosphonates in selected cases (weak recommendation)
• Surgery only in consolidated phase unless life-threatening infection

American Diabetes Association Standards of Care (2024)

• Annual comprehensive foot examination for all diabetics
• Risk stratification for Charcot development
• Patient education on self-monitoring
• Multidisciplinary team approach for established Charcot

---

12. Prevention Strategies

Primary Prevention (Preventing First Charcot Event)

Target population: All diabetics with peripheral neuropathy

Secondary Prevention (Preventing Recurrence)

Target population: Patients with history of Charcot foot

Dermal Thermometry Protocol:

• Patient uses infrared thermometer
• Measures same 6 sites on both feet daily
• If temperature difference > 2°C on 2 consecutive days → contact specialist immediately
• Reduces new ulcer incidence by 60% [36]

---

13. Multidisciplinary Team (MDT) Approach

Optimal Charcot foot care requires integrated input from multiple specialties:

Evidence for MDT: Integrated foot care services reduce major amputation rates by 50-85% compared to standard care. [35]

---

14. Patient Education and Counseling

Key Messages for Patients

Understanding the Condition:

• "Charcot foot is a serious complication of nerve damage in diabetes where bones in your foot weaken and can break without you feeling it."
• "The main danger is that you can keep walking on a broken foot because you can't feel pain, which makes it worse."

Recognizing Warning Signs:

• "Check your feet every day for redness, warmth, or swelling."
• "If one foot feels warmer than the other, stop walking immediately and contact your diabetes team."
• "A hot, red, swollen foot is an emergency, even if it doesn't hurt."

Treatment Commitment:

• "You will need to wear a special cast or boot for 3 to 6 months, possibly longer."
• "Do not remove the cast or boot, even though your foot may feel fine—removing it can cause permanent damage."
• "The cast protects your foot while the bones heal."

Long-Term Care:

• "Once healed, you will need special shoes for life to protect your feet."
• "You must never walk barefoot, even indoors."
• "Regular podiatry appointments are essential—don't skip them."

Prognosis Framing (realistic but not nihilistic):

• "If we catch it early and you follow treatment, most people avoid serious deformity."
• "Without treatment, there's a high risk of foot collapse, ulcers, and amputation."
• "Your commitment to treatment makes the biggest difference in outcome."

Shared Decision-Making

For surgical decisions:

• Explain risks: infection (20-30%), non-union (30-40%), need for amputation (10-15%)
• Discuss alternatives: prolonged conservative management, lifelong orthotic devices
• Realistic expectations: 6-12 months of limited mobility post-surgery

---

15. Special Populations

Renal Transplant Recipients

• 6-fold increased risk of Charcot foot [13]
• Multifactorial: neuropathy, immunosuppression, steroid-induced osteoporosis, hypercalcemia
• Often more aggressive course
• Requires close coordination between nephrology and diabetic foot teams

Chronic Kidney Disease (Pre-Dialysis)

• Renal osteodystrophy compounds bone fragility
• Impaired healing
• Higher cardiovascular mortality
• Optimize phosphate, calcium, vitamin D, PTH

Pregnancy (Rare)

• Case reports of Charcot foot developing or worsening in pregnancy
• Mechanism: Weight gain, ligamentous laxity (relaxin), increased stress
• Management challenging: Offloading devices cumbersome; some medications contraindicated
• Multidisciplinary care essential: obstetrics, diabetes, orthopedics

Elderly and Frail Patients

• TCC may increase falls risk
• Wheelchair or bed rest may be safer than cast immobilization
• Consider iTCC (instant total contact cast) if ambulatory
• Social support critical for compliance and safety

---

16. Controversies and Evolving Evidence

Bisphosphonates: Routine or Selective Use?

Current State:

• Small RCTs show benefit (reduced healing time, bone turnover markers)
• No large-scale trials
• NICE/IWGDF: Insufficient evidence for routine recommendation
• Some specialist centers use selectively in severe or refractory cases

Future Direction: Ongoing trials may clarify role

Surgical Timing: Early Stabilization vs. Conservative-First?

Traditional Approach: Delay surgery until Stage III (consolidated)

Emerging Concept: Selected Stage I cases with severe instability might benefit from early surgical stabilization

Evidence: Limited; case series only; risk of infection and non-union high

Consensus: Conservative management remains first-line; early surgery reserved for exceptional cases

Activity Monitoring and Compliance

Technology: Accelerometers in cast boots to objectively measure weight-bearing

Findings: Patients in removable walkers non-compliant 40-60% of time [29]

Implication: Strengthens case for non-removable TCC or iTCC

Biological Therapies

Investigational:

• Anti-TNF agents (case reports)
• Denosumab (RANKL inhibitor)
• Teriparatide (anabolic bone agent)

Status: Experimental; no trial data

---

17. Exam Scenarios and High-Yield Questions

Scenario 1: Acute Presentation

Stem: A 58-year-old man with type 2 diabetes for 14 years presents with a 3-week history of a red, swollen, warm right foot. He reports minimal pain. Examination reveals a temperature differential of 3°C compared to the left foot, bounding pedal pulses, and inability to perceive a 10g monofilament. Plain radiographs show no fracture. CRP is 22 mg/L.

Question: What is the most likely diagnosis and immediate management?

Model Answer:

• Diagnosis: Acute Charcot neuroarthropathy (Eichenholtz Stage 0 or I)
• Key features: Neuropathy, hot swollen foot, minimal pain, normal radiographs
• Differentiation from infection: CRP only mildly elevated, no systemic upset, elevation test would likely show improvement
• Immediate management:
  1. Urgent referral to diabetic foot MDT (within 1 working day per NICE NG19)
  2. Total Contact Cast or non-removable offloading device
  3. Non-weight-bearing or minimal weight-bearing with crutches
  4. MRI to detect early bone oedema if radiographs normal
  5. Serial temperature monitoring and radiographs every 2-4 weeks
  6. Optimize diabetes control, vitamin D supplementation
  7. Continue until temperature normalizes (less than 2°C difference) and clinical/radiographic consolidation (typically 3-6 months)

Scenario 2: Differential Diagnosis

Stem: How would you differentiate acute Charcot foot from cellulitis in a diabetic patient?

Model Answer:

Critical Point: Both can coexist in 20-25% of cases; presence of ulcer increases infection likelihood. Treat both if uncertain.

Scenario 3: Management Duration

Stem: When is it safe to transition a patient from Total Contact Cast to a removable walker?

Model Answer:

• Clinical criteria:
  • Skin temperature difference less than 2°C for two consecutive measurements one week apart
  • Resolution of erythema and oedema
  • No increase in temperature or swelling with mobilization
• Radiographic criteria:
  • Evidence of bony consolidation (Stage II-III)
  • No progression of fracture or subluxation
• Timeline: Typically 3-6 months, though can be > 12 months
• Transition protocol:
  • Gradual return to weight-bearing in CROW walker or custom AFO
  • Daily home temperature monitoring (patient-performed)
  • If temperature difference increases to > 2°C, return to TCC
  • Serial X-rays every 4-6 weeks during transition
• Final stage: Custom therapeutic footwear with molded insoles (lifelong)

Scenario 4: Viva Question - Pathophysiology

Question: Explain the pathophysiological mechanisms underlying Charcot neuroarthropathy.

Model Answer:

Dual mechanisms (neurotraumatic and neurovascular):

1. Neurotraumatic Theory:

• Peripheral sensory neuropathy → loss of protective sensation
• Repetitive microtrauma during weight-bearing goes unperceived
• Absence of pain → continued ambulation on microfractured bones
• Progressive bone and joint destruction

2. Neurovascular Theory:

• Autonomic neuropathy → loss of sympathetic tone
• Arteriovenous shunting → increased bone blood flow (hyperperfusion)
• Enhanced osteoclastic activity → periarticular osteopenia
• Bones weaken and fracture with normal stress

3. Molecular Mechanisms:

• RANKL-RANK-OPG axis dysregulation:
  • RANKL (receptor activator of nuclear factor-κB ligand) elevated
  • RANKL binds RANK on osteoclasts → enhanced bone resorption
  • OPG (osteoprotegerin, natural inhibitor) relatively deficient
  • Pro-osteoclastic environment accelerates bone destruction
• Inflammatory cytokines (TNF-α, IL-1β, IL-6) promote inflammation and bone resorption

4. Clinical Manifestation:

• Combination of mechanical trauma + biological predisposition
• Results in bone fragmentation, joint dislocation, architectural collapse
• "Hot foot" due to increased blood flow
• Painless destruction due to neuropathy

Summary: Loss of sensation allows repetitive trauma, while vascular dysregulation and inflammatory mediators actively weaken bone, creating a perfect storm for joint destruction.

Scenario 5: Imaging Interpretation

Stem: An MRI of a diabetic foot shows bone marrow oedema at the tarsometatarsal joints bilaterally with joint effusion and soft tissue oedema. There is a 1 cm plantar ulcer over the 5th metatarsal head. How would you interpret this?

Model Answer:

Interpretation:

• Primary diagnosis: Acute Charcot neuroarthropathy (Lisfranc pattern, Sanders-Frykberg Type II)
  • Periarticular bone marrow oedema typical of Charcot
  • Joint effusion supports acute inflammatory phase
  • Bilateral involvement unusual but can occur

Critical Consideration: Concurrent osteomyelitis must be excluded given the ulcer

• Plantar ulcer provides direct access for bacteria to bone
• Probe-to-bone test: Essential—if positive, sensitivity 87% for osteomyelitis
• MRI cannot reliably differentiate Charcot from osteomyelitis (specificity ~50-60%)

Diagnostic Approach:

1. Probe-to-bone test in clinic
2. Inflammatory markers (WCC, CRP, ESR)—elevated CRP > 100 favours infection
3. Clinical features: Fever, purulent discharge, systemic upset suggest infection
4. Consider bone biopsy if diagnostic uncertainty (gold standard for osteomyelitis)

Management:

• If infection suspected: Treat both Charcot AND osteomyelitis
  • Offloading (TCC)
  • Antibiotics (6-12 weeks)
  • Surgical debridement if needed
• If infection excluded: TCC alone

Key Principle: When in doubt, treat both conditions—untreated osteomyelitis leads to amputation.

---

18. Audit Standards and Quality Metrics

NICE Quality Standard QS15 (Diabetic Foot Problems)

Local Audit Cycle (Suggested)

Audit Question: Are patients with acute Charcot foot receiving evidence-based care in accordance with NICE NG19?

Standards:

1. Time from presentation to specialist assessment less than 1 week
2. TCC or iTCC applied within 2 weeks of diagnosis
3. Duration of offloading ≥3 months
4. Temperature normalization documented before cast removal
5. Provision of custom footwear on discharge

Data Collection: Retrospective case note review over 12 months

Re-audit: After interventions to close audit loop

---

19. Historical Context and Eponymous Legacy

Jean-Martin Charcot (1825-1893)

Jean-Martin Charcot, the eminent French neurologist, first described neuropathic arthropathy in 1868 in patients with tabes dorsalis (tertiary syphilis affecting the dorsal columns of the spinal cord). He observed that patients with profound sensory loss developed rapid, painless destruction of joints, particularly in the lower limbs and spine.

Original Charcot Triad (for tabes dorsalis, not diabetic Charcot foot):

1. Ataxia (loss of proprioception)
2. Lightening pains
3. Hypotonia

The neuropathic joint destruction was subsequently termed "Charcot joint" or "Charcot arthropathy."

Epidemiological Shift: Syphilis to Diabetes

In the early 20th century, syphilis (specifically tabes dorsalis) was the dominant cause of Charcot joints, affecting spine and large lower limb joints (hip, knee, ankle). With the advent of penicillin in the 1940s and effective treatment of syphilis, tabes dorsalis became rare.

Concurrently, the prevalence of diabetes mellitus rose dramatically in the 20th century. By the 1960s, diabetic neuropathy had emerged as the leading cause of Charcot arthropathy, now predominantly affecting the foot rather than proximal joints. Today, > 95% of Charcot arthropathy cases are diabetic in origin.

Modern Terminology

While "Charcot foot" and "Charcot joint" are widely used, the preferred medical term is "Charcot neuroarthropathy" or "neuropathic osteoarthropathy" to reflect the underlying pathophysiology and broader spectrum of causative neuropathies beyond diabetes alone.

---

20. Patient Resources and Support Organizations

UK Resources

• Diabetes UK: www.diabetes.org.uk

  • Patient information on Charcot foot
  • "Helpline: 0345 123 2399"

• NHS Diabetic Foot Screening Programme: Annual screening for at-risk patients

• National Institute for Health and Care Excellence (NICE): Patient decision aids and information leaflets

International Resources

• American Diabetes Association: www.diabetes.org

  • Foot care guidelines for patients

• International Diabetes Federation: www.idf.org

  • Global diabetes education resources

Support Groups

• Diabetes UK online forum: Peer support from others with diabetic complications
• Local diabetic foot clinics: Often provide group education sessions

---

21. Future Directions and Research Priorities

Current Research Gaps

1. Biomarkers for early detection (TNF-α, RANKL, bone turnover markers—validation studies needed)
2. Optimal bisphosphonate regimen (dose, duration, patient selection)
3. Genetic susceptibility (why do only some neuropathic patients develop Charcot?)
4. Imaging algorithms (MRI vs. PET vs. WBC scan for osteomyelitis differentiation)
5. Novel therapies:
   • Anti-RANKL biologics (denosumab)
   • Anti-TNF agents
   • Anabolic bone therapies (teriparatide)
6. Health economics (cost-effectiveness of early specialist intervention vs. delayed care and amputation)

Emerging Technologies

• Wearable sensors for continuous temperature and pressure monitoring
• Smartphone-based thermography for home monitoring
• 3D-printed custom orthoses for improved fit and accessibility
• Telemedicine for remote surveillance and specialist access in underserved areas

Trial Needs

• Large-scale RCTs comparing:
  • TCC vs. iTCC vs. RCW (objective compliance monitoring)
  • Bisphosphonates vs. placebo
  • Early surgery vs. conservative management in severe instability
  • Novel biological therapies vs. standard care

Challenge: Ethical difficulty of placebo/no-treatment arms given established benefit of offloading

---

22. Summary: Key Take-Home Messages

1. Charcot foot is a clinical diagnosis in the hot, red, swollen, painless foot of a patient with diabetic neuropathy—think Charcot first, not just infection.

2. The elevation test (redness improves with elevation in Charcot, persists in infection) is a simple bedside differentiator, though both conditions can coexist.

3. Early diagnosis and immediate offloading are paramount: Total Contact Cast until temperature normalizes (less than 2°C difference) and radiographic consolidation (3-6 months average).

4. Rocker-bottom deformity is preventable with early, aggressive offloading—but once established, carries 40-60% risk of ulceration and high amputation risk.

5. Multidisciplinary team care (diabetologist, podiatrist, orthotist, surgeon) reduces amputation rates by 50-85%.

6. Lifelong protective footwear and surveillance are essential after healing to prevent recurrence and complications.

7. 5-year mortality approaches 30%, comparable to many cancers—Charcot foot is a marker of severe systemic disease and requires holistic management.

8. Patient education and compliance are the most important modifiable factors determining outcome—invest time in counseling.

---

23. References

1. Rogers LC, Frykberg RG, Armstrong DG, et al. The Charcot foot in diabetes. Diabetes Care. 2011;34(9):2123-2129. doi:10.2337/dc11-0844 [PMID: 21868780]

2. Jeffcoate WJ. Charcot neuro-osteoarthropathy. Diabetes Metab Res Rev. 2008;24 Suppl 1:S62-S65. doi:10.1002/dmrr.837 [PMID: 18442185]

3. Sohn MW, Lee TA, Stuck RM, Frykberg RG, Budiman-Mak E. Mortality risk of Charcot arthropathy compared with that of diabetic foot ulcer and diabetes alone. Diabetes Care. 2009;32(5):816-821. doi:10.2337/dc08-1695 [PMID: 19196896]

4. Wukich DK, Sung W. Charcot arthropathy of the foot and ankle: modern concepts and management review. J Diabetes Complications. 2009;23(6):409-426. doi:10.1016/j.jdiacomp.2008.09.004 [PMID: 19022666]

5. Fabrin J, Larsen K, Holstein PE. Long-term follow-up in diabetic Charcot feet with spontaneous onset. Diabetes Care. 2000;23(6):796-800. doi:10.2337/diacare.23.6.796 [PMID: 10841000]

6. Game FL, Catlow R, Jones GR, et al. Audit of acute Charcot's disease in the UK: the CDUK study. Diabetologia. 2012;55(1):32-35. doi:10.1007/s00125-011-2354-7 [PMID: 22002007]

7. van Baal J, Hubbard R, Game F, Jeffcoate W. Mortality associated with acute Charcot foot and neuropathic foot ulceration. Diabetes Care. 2010;33(5):1086-1089. doi:10.2337/dc09-1428 [PMID: 20150290]

8. Stuck RM, Sohn MW, Budiman-Mak E, Lee TA, Weiss KB. Charcot arthropathy risk elevation in the obese diabetic population. Am J Med. 2008;121(11):1008-1014. doi:10.1016/j.amjmed.2008.06.038 [PMID: 18954850]

9. Armstrong DG, Todd WF, Lavery LA, Harkless LB, Bushman TR. The natural history of acute Charcot's arthropathy in a diabetic foot specialty clinic. Diabet Med. 1997;14(5):357-363. doi:10.1002/(SICI)1096-9136(199705)14:5less than 357::AID-DIA341> 3.0.CO;2-8 [PMID: 9171248]

10. Lavery LA, Armstrong DG, Wunderlich RP, Tredwell J, Boulton AJ. Diabetic foot syndrome: evaluating the prevalence and incidence of foot pathology in Mexican Americans and non-Hispanic whites from a diabetes disease management cohort. Diabetes Care. 2003;26(5):1435-1438. doi:10.2337/diacare.26.5.1435 [PMID: 12716801]

11. Trieb K. The Charcot foot: pathophysiology, diagnosis and classification. Bone Joint J. 2016;98-B(9):1155-1159. doi:10.1302/0301-620X.98B9.37038 [PMID: 27587513]

12. Leung HB, Ho YC, Wong WC. Charcot foot in a Hong Kong Chinese diabetic population. Hong Kong Med J. 2009;15(3):191-195. [PMID: 19509437]

13. Petrova NL, Foster AV, Edmonds ME. Calcaneal bone mineral density in patients with Charcot neuropathic osteoarthropathy: differences between Type 1 and Type 2 diabetes. Diabet Med. 2005;22(6):756-761. doi:10.1111/j.1464-5491.2005.01505.x [PMID: 15910628]

14. Rajbhandari SM, Jenkins RC, Davies C, Tesfaye S. Charcot neuroarthropathy in diabetes mellitus. Diabetologia. 2002;45(8):1085-1096. doi:10.1007/s00125-002-0885-7 [PMID: 12189439]

15. Koeck FX, Bobrik V, Fassold A, et al. High prevalence of Charcot neuroarthropathy in patients with diabetes mellitus and polyneuropathy. Foot Ankle Surg. 2019;25(5):630-634. doi:10.1016/j.fas.2018.07.004 [PMID: 30297065]

16. Uccioli L, Sinistro A, Almerighi C, et al. Proinflammatory modulation of the surface and cytokine phenotype of monocytes in patients with acute Charcot foot. Diabetes Care. 2010;33(2):350-355. doi:10.2337/dc09-1141 [PMID: 19933992]

17. Mabilleau G, Petrova NL, Edmonds ME, Sabokbar A. Increased osteoclastic activity in acute Charcot's osteoarthropathy: the role of receptor activator of nuclear factor-kappaB ligand. Diabetologia. 2008;51(6):1035-1040. doi:10.1007/s00125-008-0992-1 [PMID: 18369590]

18. Petrova NL, Petrov PK, Edmonds ME. Inhibition of TNF-α reverses the pathological resorption pit profile of osteoclasts from patients with acute Charcot osteoarthropathy. J Diabetes Res. 2015;2015:917945. doi:10.1155/2015/917945 [PMID: 26491700]

19. Chantelau EA, Richter A, Schmidt-Grigoriadis P, Scherbaum WA. The diabetic Charcot foot: MRI discloses bone stress injury as trigger mechanism of neuroarthropathy. Exp Clin Endocrinol Diabetes. 2006;114(3):118-123. doi:10.1055/s-2006-923922 [PMID: 16636972]

20. Frykberg RG, Belczyk R. Epidemiology of the Charcot foot. Clin Podiatr Med Surg. 2008;25(1):17-28. doi:10.1016/j.cpm.2007.10.001 [PMID: 18165108]

21. Pakarinen TK, Laine HJ, Honkonen SE, Peltonen J, Oksala H, Lahtela J. Charcot arthropathy of the diabetic foot. Current concepts and review of 36 cases. Scand J Surg. 2002;91(2):195-201. doi:10.1177/145749690209100211 [PMID: 12164523]

22. Donohoe KJ, Henkin RE, Royal HD, et al. Procedure guideline for bone scintigraphy: 1.0. J Nucl Med. 2003;44(12):2107-2111. [PMID: 14660737]

23. Myerson MS, Henderson MR, Saxby T, Short KW. Management of midfoot diabetic neuroarthropathy. Foot Ankle Int. 1994;15(5):233-241. doi:10.1177/107110079401500503 [PMID: 7951960]

24. Ahmadi ME, Morrison WB, Carrino JA, Schweitzer ME, Raikin SM, Ledermann HP. Neuropathic arthropathy of the foot with and without superimposed osteomyelitis: MR imaging characteristics. Radiology. 2006;238(2):622-631. doi:10.1148/radiol.2382041393 [PMID: 16436821]

25. Grayson ML, Gibbons GW, Balogh K, Levin E, Karchmer AW. Probing to bone in infected pedal ulcers. A clinical sign of underlying osteomyelitis in diabetic patients. JAMA. 1995;273(9):721-723. [PMID: 7853630]

26. Eichenholtz SN. Charcot Joints. Springfield, IL: Charles C Thomas; 1966.

27. Stuck RM, Sohn MW, Budiman-Mak E, Lee TA, Weiss KB. Charcot arthropathy risk elevation in the obese diabetic population. Am J Med. 2008;121(11):1008-1014. doi:10.1016/j.amjmed.2008.06.038 [PMID: 18954850]

28. Armstrong DG, Lavery LA, Wu S, Boulton AJ. Evaluation of removable and irremovable cast walkers in the healing of diabetic foot wounds: a randomized controlled trial. Diabetes Care. 2005;28(3):551-554. doi:10.2337/diacare.28.3.551 [PMID: 15735186]

29. Armstrong DG, Lavery LA, Kimbriel HR, Nixon BP, Boulton AJ. Activity patterns of patients with diabetic foot ulceration: patients with active ulceration may not adhere to a standard pressure off-loading regimen. Diabetes Care. 2003;26(9):2595-2597. doi:10.2337/diacare.26.9.2595 [PMID: 12941724]

30. Pitocco D, Ruotolo V, Caputo S, et al. Six-month treatment with alendronate in acute Charcot neuroarthropathy: a randomized controlled trial. Diabetes Care. 2005;28(5):1214-1215. doi:10.2337/diacare.28.5.1214 [PMID: 15855602]

31. Pinzur MS, Sage R, Stuck R, Kaminsky S, Zmuda A. A treatment algorithm for neuropathic (Charcot) midfoot deformity. Foot Ankle Int. 1993;14(4):189-197. doi:10.1177/107110079301400403 [PMID: 8519033]

32. Frykberg RG, Zgonis T, Armstrong DG, et al. Diabetic foot disorders: a clinical practice guideline (2006 revision). J Foot Ankle Surg. 2006;45(5 Suppl):S1-S66. doi:10.1016/S1067-2516(07)60001-5 [PMID: 17280936]

33. Pakarinen TK, Laine HJ, Mäenpää H, Mattila P, Lahtela J. The effect of zoledronic acid on the clinical resolution of Charcot neuroarthropathy: a pilot randomized controlled trial. Diabetes Care. 2011;34(7):1514-1516. doi:10.2337/dc11-0396 [PMID: 21593290]

34. Sinacore DR, Withrington NC. Recognition and management of acute neuropathic (Charcot) arthropathies of the foot and ankle. J Orthop Sports Phys Ther. 1999;29(12):736-746. doi:10.2519/jospt.1999.29.12.736 [PMID: 10612071]

35. Krishnan S, Nash F, Baker N, Fowler D, Rayman G. Reduction in diabetic amputations over 11 years in a defined U.K. population: benefits of multidisciplinary team work and continuous prospective audit. Diabetes Care. 2008;31(1):99-101. doi:10.2337/dc07-1178 [PMID: 17934146]

36. Lavery LA, Higgins KR, Lanctot DR, et al. Preventing diabetic foot ulcer recurrence in high-risk patients: use of temperature monitoring as a self-assessment tool. Diabetes Care. 2007;30(1):14-20. doi:10.2337/dc06-1600 [PMID: 17192326]

37. Bus SA, Waaijman R, Arts M, et al. Effect of custom-made footwear on foot ulcer recurrence in diabetes: a multicenter randomized controlled trial. Diabetes Care. 2013;36(12):4109-4116. doi:10.2337/dc13-0996 [PMID: 24130354]

---

24. Patient/Layperson Explanation

What is Charcot Foot?

Charcot foot is a serious complication of diabetes where the bones in your foot gradually weaken, break, and collapse because you cannot feel pain properly. The nerve damage from diabetes (called neuropathy) means you don't feel when you injure your foot, so you keep walking on broken bones, making the problem much worse.

What are the Symptoms?

• Hot, red, swollen foot: Your foot may become very warm, red, and puffy
• Minimal or no pain: Because of nerve damage, your foot might not hurt even though it's seriously injured
• Change in foot shape: Over time, your foot may collapse and become deformed if not treated

How is it Treated?

1. Special cast or boot (Total Contact Cast): You'll wear a protective cast that you cannot remove for 3-6 months to allow the bones to heal without bearing weight
2. Stop walking on it: You must avoid putting weight on the affected foot—this is the most important part of treatment
3. Custom shoes for life: After healing, you'll need specially designed shoes to protect your feet forever
4. Regular check-ups: You'll see specialists (podiatrist, diabetes doctor) regularly to monitor your feet

What Happens if It's Not Treated?

Without treatment, the bones in your foot will collapse into a "rocker-bottom" shape. This creates pressure points that lead to:

• Foot ulcers (open sores)
• Infections
• Risk of amputation (surgical removal of part of your foot or leg)

What Can You Do?

1. Check your feet every single day: Look for redness, warmth, swelling, or cuts
2. Never walk barefoot: Always wear protective footwear, even indoors
3. See your doctor immediately if: Your foot becomes hot, red, or swollen—this is an emergency
4. Follow treatment strictly: Don't remove your cast or stop wearing protective devices early
5. Control your blood sugar: Good diabetes control helps prevent complications
6. Don't smoke: Smoking damages blood vessels and worsens healing

Key Message

Charcot foot is very serious, but if caught early and treated properly, most people can prevent permanent damage and avoid amputation. The success depends on your commitment to following treatment—wearing the cast, not walking on the foot, and using special shoes afterward.

---

Medical Disclaimer: This content is for educational purposes and clinical reference only. Always consult with a healthcare professional for medical advice, diagnosis, or treatment. If you suspect you have Charcot foot, seek urgent specialist medical attention.